



Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Hiroyuki Okuzawa, Representative Director, President and CEO
(Code no.: 4568, Prime Market, Tokyo Stock Exchange)
Please address inquiries to Ari Fujishiro, Corporate Officer,
Head of Investor Relations and Shareholder Relations Department
Telephone: for media +81-3-6225-1126
for stock market participants +81-3-6225-1125

(Correction) Notice of Partial Correction to the Presentation Material for FY2025 Financial Results and 5-Year Business Plan Presentation & Discussion (FY2026-FY2030) and the FY2025 Reference Data

Tokyo, Japan (May 13, 2026) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) hereby announces that there have been corrections to the Presentation Material for FY2025 Financial Results and 5-Year Business Plan Presentation & Discussion (FY2026-FY2030) and the FY2025 Reference Data, disclosed on May 11, 2026. There are no corrections to the previously released the Consolidated Financial Results for the Year Ended March 31, 2026. The corrected documents are available on our website:

https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025%20Financial%20Results%20and%205Year%20Business%20Plan%20Presentation_E_v2.pdf

https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025Q4_Reference_Data_E_v2.pdf

1. Reason for Corrections

We are issuing corrections as it has been discovered that there are errors in a part of the contents disclosed in our previous announcement.


2. Details of Corrections (The areas marked by red dotted lines indicate the corrections)

- Presentation Material for FY2025 Financial Results and 5-Year Business Plan Presentation & Discussion (FY2026-FY2030)

Page 31: Percentage of shares transferred

<Before corrections>

Initiatives Related to Profit Growth for Current Business and Products in Japan



Focusing resources on innovative pharmaceuticals business

- ◆ **Stock Transfer of DAIICHI SANKYO HEALTHCARE CO., LTD. (Concluded an agreement in April 2026)**
 - Transferee: Suntory Holdings Limited
 - Consideration for transfer (planned) : 246.5 Bn JPY
 - Date of transfer (planned) :
 - June 1, 2026 (30% of the shares held by the Company),
 - June 1, 2027 (40% of the shares held by the Company),
 - June 1, 2029 (40% of the shares held by the Company)
 - Impact on Consolidated Financial Results (planned) :

The company expects to recognize gain on the stock transfer as non-core income in FY2027

31

<After corrections>

Initiatives Related to Profit Growth for Current Business and Products in Japan



Focusing resources on innovative pharmaceuticals business

- ◆ **Stock Transfer of DAIICHI SANKYO HEALTHCARE CO., LTD. (Concluded an agreement in April 2026)**
 - Transferee: Suntory Holdings Limited
 - Consideration for transfer (planned) : 246.5 Bn JPY
 - Date of transfer (planned) :
 - June 1, 2026 (30% of the shares held by the Company),
 - June 1, 2027 (40% of the shares held by the Company),
 - June 1, 2029 (30% of the shares held by the Company)
 - Impact on Consolidated Financial Results (planned) :

The company expects to recognize gain on the stock transfer as non-core income in FY2027

31

● FY2025 Reference Data

Page 11: Current liabilities as of the end of March 2026

<Before corrections>

<Liabilities and equity>				JPY Bn
	Mar. 2025	Mar. 2026	vs. Mar. 2025	
Liabilities				
Current liabilities				
Trade and other payables	580.0	596.9	16.9	
Bonds and borrowings	0.4	0.4	0.0	
Other financial liabilities	14.7	13.6	-1.1	
Income taxes payable	60.4	88.3	27.9	
Provisions	5.8	49.8	44.0	
Contract liabilities	68.0	74.4	6.4	
Other current liabilities	24.8	30.1	5.2	
Total current liabilities	754.0	885.0	131.0	
Non-current liabilities				
Bonds and borrowings	100.9	300.1	199.1	Corporate bonds +200.0
Other financial liabilities	43.7	39.2	-4.5	
Post employment benefit liabilities	1.6	1.5	-0.1	
Provisions	13.0	164.6	151.5	
Contract liabilities	751.0	806.8	55.8	Deferred revenue for trastuzumab deruxtecan -8.0 (Strategic collaboration upfront payment -10.2, Regulatory milestone payment/Quid +9.4)
Deferred tax liabilities	11.1	3.2	-7.8	Deferred revenue for datopotamab deruxtecan -1.8 (Strategic collaboration upfront payment -6.4, Regulatory milestone payment +4.5)
Other non-current liabilities	157.4	140.8	-16.5	Deferred revenue for US MRK alliance +63.3
Total non-current liabilities	1,078.7	1,456.2	377.5	
Total liabilities	1,832.7	2,341.2	508.5	
Equity				
Equity attributable to owners of the Company				
Share capital	50.0	50.0	-	Acquisition of own shares (DS) -106.5, Acquisition of own shares (share delivery trust) -43.9, Cancellation of own shares +49.0
Own shares	-147.3	-248.0	-100.7	
Other components of equity	263.7	311.6	47.9	Currency translation difference +50.4, Valuation difference on financial assets -2.4
Retained earnings	1,457.0	1,550.6	93.5	
Total equity attributable to owners of the Company	1,623.4	1,664.2	40.8	Profit for the period +259.8, Payment of dividends -128.5, Cancellation of own shares -40.3
Total equity	1,623.4	1,664.2	40.8	
Total liabilities and equity	3,456.1	4,005.4	549.3	

<After corrections>

<Liabilities and equity>				JPY Bn
	Mar. 2025	Mar. 2026	vs. Mar. 2025	
Liabilities				
Current liabilities				
Trade and other payables	580.0	596.9	16.9	
Bonds and borrowings	0.4	0.4	0.0	
Other financial liabilities	14.7	13.6	-1.1	
Income taxes payable	60.4	88.3	27.9	
Provisions	5.8	49.8	44.0	
Contract liabilities	68.0	74.4	6.4	
Other current liabilities	24.8	30.1	5.2	
Subtotal	754.0	853.5	99.4	
Liabilities directly associated with assets held for sale	-	31.6	31.6	
Total current liabilities	754.0	885.0	131.0	
Non-current liabilities				
Bonds and borrowings	100.9	300.1	199.1	Corporate bonds +200.0
Other financial liabilities	43.7	39.2	-4.5	
Post employment benefit liabilities	1.6	1.5	-0.1	
Provisions	13.0	164.6	151.5	
Contract liabilities	751.0	806.8	55.8	Deferred revenue for trastuzumab deruxtecan -8.0 (Strategic collaboration upfront payment -10.2, Regulatory milestone payment/Quid +9.4)
Deferred tax liabilities	11.1	3.2	-7.8	Deferred revenue for datopotamab deruxtecan -1.8 (Strategic collaboration upfront payment -6.4, Regulatory milestone payment +4.5)
Other non-current liabilities	157.4	140.8	-16.5	Deferred revenue for US MRK alliance +63.3
Total non-current liabilities	1,078.7	1,456.2	377.5	
Total liabilities	1,832.7	2,341.2	508.5	
Equity				
Equity attributable to owners of the Company				
Share capital	50.0	50.0	-	Acquisition of own shares (DS) -106.5, Acquisition of own shares (share delivery trust) -43.9, Cancellation of own shares +49.0
Own shares	-147.3	-248.0	-100.7	
Other components of equity	263.7	311.6	47.9	Currency translation difference +50.4, Valuation difference on financial assets -2.4
Retained earnings	1,457.0	1,550.6	93.5	
Total equity attributable to owners of the Company	1,623.4	1,664.2	40.8	Profit for the period +259.8, Payment of dividends -128.5, Cancellation of own shares -40.3
Total equity	1,623.4	1,664.2	40.8	
Total liabilities and equity	3,456.1	4,005.4	549.3	